Next Article in Journal
Innovative Cancer Immunotherapy with MAGE-A3 mRNA Cancer Vaccines
Previous Article in Journal
Altered Microbiome Promotes Pro-Inflammatory Pathways in Oesophago-Gastric Tumourigenesis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16, 998

by
Julia Chisholm
1,*,†,
Henry Mandeville
1,†,
Madeleine Adams
2,
Veronique Minard-Collin
3,
Timothy Rogers
4,
Anna Kelsey
5,
Janet Shipley
6,
Rick R. van Rijn
7,
Isabelle de Vries
8,
Roelof van Ewijk
8,
Bart de Keizer
8,
Susanne A. Gatz
9,10,
Michela Casanova
11,
Lisa Lyngsie Hjalgrim
12,
Charlotte Firth
10,
Keith Wheatley
10,
Pamela Kearns
10,
Wenyu Liu
10,
Amanda Kirkham
10,
Helen Rees
13,
Gianni Bisogno
14,
Ajla Wasti
6,
Sara Wakeling
15,
Delphine Heenen
16,
Deborah A. Tweddle
17,
Johannes H. M. Merks
8,‡ and
Meriel Jenney
2,‡
add Show full author list remove Hide full author list
1
Children and Young People’s Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton SM2 5PT, UK
2
Children’s Hospital for Wales, Cardiff CF14 4XW, UK
3
Department of Paediatric Oncology, Gustave Roussy, 75015 Paris, France
4
Department of Paediatric Surgery, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol BS1 3NU, UK
5
Department of Paediatric Histopathology, Royal Manchester Children’s Hospital, Manchester University NHS Foundation Trust, Manchester M13 9WL, UK
6
The Institute of Cancer Research, London SW7 3RP, UK
7
Department of Radiology and Nuclear Medicine, University of Amsterdam, Amsterdam UMC, 1081 HV Amsterdam, The Netherlands
8
Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
9
Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham B15 2TG, UK
10
Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK
11
Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy
12
University Hospital Copenhagen, DK-2200 Copenhagen, Denmark
13
Department of Paediatric Oncology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol BS1 3NU, UK
14
Department of Women and Children’s Health, University of Padova, 35122 Padua, Italy
15
Alice’s Arc Charity, London EC1V 1AW, UK
16
KickCancer Foundation, 1000 Brussels, Belgium
17
Vivo Biobank, Translational & Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
These authors contributed equally to this work.
Cancers 2024, 16(19), 3427; https://doi.org/10.3390/cancers16193427
Submission received: 5 August 2024 / Accepted: 10 September 2024 / Published: 9 October 2024
The authors wish to make corrections to the authorship and title of [1]. The corrected authorship is as follows: Julia Chisholm and Henry Mandeville contributed equally to the first authorship. Hans Merks and Meriel Jenney contributed equally to senior authorship. In the title FAR-RMS has been corrected to FaR-RMS.
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Chisholm, J.; Mandeville, H.; Adams, M.; Minard-Collin, V.; Rogers, T.; Kelsey, A.; Shipley, J.; van Rijn, R.R.; de Vries, I.; van Ewijk, R.; et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16, 998. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Chisholm, J.; Mandeville, H.; Adams, M.; Minard-Collin, V.; Rogers, T.; Kelsey, A.; Shipley, J.; van Rijn, R.R.; de Vries, I.; van Ewijk, R.; et al. Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16, 998. Cancers 2024, 16, 3427. https://doi.org/10.3390/cancers16193427

AMA Style

Chisholm J, Mandeville H, Adams M, Minard-Collin V, Rogers T, Kelsey A, Shipley J, van Rijn RR, de Vries I, van Ewijk R, et al. Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16, 998. Cancers. 2024; 16(19):3427. https://doi.org/10.3390/cancers16193427

Chicago/Turabian Style

Chisholm, Julia, Henry Mandeville, Madeleine Adams, Veronique Minard-Collin, Timothy Rogers, Anna Kelsey, Janet Shipley, Rick R. van Rijn, Isabelle de Vries, Roelof van Ewijk, and et al. 2024. "Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16, 998" Cancers 16, no. 19: 3427. https://doi.org/10.3390/cancers16193427

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop